Dr. Catalona's Prostate Cancer Information Site

Please consider a donation to the URF

Dr. Catalona's Journal Articles

The way to see the most up to date list with summaries of Dr. Catalona's journal articles which address topics of high interest for those concerned with prostate cancer diagnosis, treatment and research is to go to www.pubmed.com and search on "catalona w" You will see a list of publications that is continuously updated, and by clicking on the publication, you can see an abstract/summary of the article.

Below, in our website, see a selection of past journal articles written by Dr. Catalona and his collaborators.

While some listings include the complete article, many provide an abstract or summary of the article, but not the complete article because copyright is owned by the journal and not by Dr. Catalona. While some articles are available in full from publications, in other cases, you may need to subscribe to a journal in order to access the complete article.

Journal Articles of High Interest

Additional Journal Articles
Article 1 of 50
Potency, Continence And Complications In 3,477 Consecutive Radical Retropubic Prostatectomies - J. Urol. 2004 Dec;172 :2227-2231
ABSTRACT Purpose: We report results in a series of 3,477 consecutive patients treated with anatomical nerve sparing radical retropubic prostatectomy (RRP) in terms of recovery of erectile function, urinary continence and postoperative complication... journal/JournalUrology_potency_3477.pdf Back to top
Article 2 of 50
Cancer Progression And Survival Rates Following Anatomical Radical Retropubic Prostatectomy In 3,478 Consecutive Patients: Long-Term Results - J Urol. 2004 Sept;172 :910-914
ABSTRACT Purpose: We updated a long-term cancer control outcome in a large anatomical radical retropubic prostatectomy (RRP) series. We also evaluated the perioperative parameters that predict cancer specific outcomes following surgery. Materials... journal/Rec_Surv_paper.pdf Back to top
Article 3 of 50
Serum pro prostate specific antigen improves cancer detection compared to free and complexed prostate specific antigen in men with prostate specific antigen 2 to 4 ng/ml. - J Urol. 2003 Dec;170(6 Pt 1):2181-5.
PURPOSE: Pro prostate specific antigen (pPSA) is a precursor form of PSA enriched in tumor compared to benign prostate tissues that may be a more specific serum marker for prostate cancer. Serum pPSA was measured in the clinically relevant ... Back to top
Article 4 of 50
Genome-wide scan of brothers: Replication and fine mapping of prostate cancer susceptibility and aggressiveness loci. - Prostate. 2003 Dec 1;57(4):298-308.
BACKGROUND: Substantial evidence suggests that genetic factors play an important role in both the risk of prostate cancer and its biologic aggressiveness. Here we investigate prostate cancer susceptibility and aggressiveness with genome-wid... Back to top
Article 5 of 50
Effect of verification bias on screening for prostate cancer by measurement of prostate-specific antigen. - N Engl J Med. 2003 Jul 24;349(4):335-42.
BACKGROUND: The sensitivity and specificity of a screening test are biased when disease status is not verified in all subjects and when the likelihood of confirmation depends on the test result itself. We assessed the screening characterist... Back to top
Article 6 of 50
Association between genetic polymorphisms in the prostate-specific antigen gene promoter and serum prostate-specific antigen levels. - J Natl Cancer Inst. 2003 Jul 16;95(14):1044-53.
BACKGROUND: Recent evidence suggests that genetic variation in the promoter of the prostate-specific antigen (PSA) gene may contribute to individual variation in serum PSA levels. However, polymorphisms associated with variations in PSA lev... Back to top
Article 7 of 50
CDKN1A and CDKN1B polymorphisms and risk of advanced prostate carcinoma. - Cancer Res. 2003 May 1;63(9):2033-6.
A multigenic model of prostate cancer susceptibility has been proposed, in which common polymorphic variants of genes, such as the androgen and vitamin D receptor, contribute to tumorigenesis. The discovery of additional genetic factors that contribu... Back to top
Article 8 of 50
Prostate cancer aggressiveness locus on chromosome segment 19q12-q13.1 identified by linkage and allelic imbalance studies. - Genes Chromosomes Cancer. 2003 Apr;36(4):332-9.
Whole-genome scan studies recently identified a locus on chromosome segments 19q12-q13.11 linked to prostate tumor aggressiveness by use of the Gleason score as a quantitative trait. We have now completed finer-scale linkage mapping across this regio... Back to top
Article 9 of 50
RNASEL Arg462Gln variant is implicated in up to 13% of prostate cancer cases. - Nat Genet. 2002 Dec;32(4):581-3. Epub 2002 Nov 04.
RNASEL (encoding ribonuclease L) has recently been proposed as a candidate for the hereditary prostate cancer (HPC1) gene. We determined that the RNASEL variant Arg462Gln has three times less enzymatic activity than the wildtype and is significantly ... Back to top
Article 10 of 50
Replication linkage study for prostate cancer susceptibility genes. - Prostate. 2000 Oct 1;45(2):106-14.
BACKGROUND: Since the publication of the first genome screen for prostate cancer (CaP) 5 years ago, over a dozen linkage studies have appeared. Most attention has been directed to chromosome 1, where two separate regions have been identifie... Back to top
Article 11 of 50
A prospective randomized trial comparing 6 versus 12 prostate biopsy cores: impact on cancer detection. - J Urol. 2000 Aug;164(2):388-92.
PURPOSE: Several studies suggest that sextant transrectal ultrasound guided biopsy of the prostate provides insufficient material to detect all clinically important prostate cancer, and obtaining more biopsy cores may improve the cancer det... Back to top
Article 12 of 50
Early Onset Prostate Cancer: Predictors Of Clinical Grade - THE JOURNAL OF UROLOGY 2002;167:1659-1663
Purpose: Prostate cancer is typically a disease of elderly men and, therefore, it has not been well characterized in those affected at a young age. With the advent of serum prostate specific antigen testing, we are able to detect prostate c... Back to top
Article 13 of 50
Frequent and early loss of the EGR1 corepressor NAB2 in human prostate carcinoma. - Human Pathology. 32(9):935-9, 2001 Sep.
The transcription factor EGR1 is frequently overexpressed in human prostate cancer and regulates the expression of several genes important for tumor progression. In addition, mice lacking the Egr1 gene show a defect in prostate tumorigenesis. NAB2... Back to top
Article 14 of 50
Expression profiling reveals hepsin overexpression in prostate cancer. - Cancer Research. 61(15):5692-6, 2001 Aug 1.
Prostate cancer is the most commonly diagnosed noncutaneous cancer in men. Despite this fact, many of the genetic changes that coincide with prostate cancer progression remain enigmatic. We have addressed this problem by characterizing the expression... Back to top
Article 15 of 50
Model-free linkage analysis with covariates confirms linkage of prostate cancer to chromosomes 1 and 4. - American Journal of Human Genetics. 68(5):1197-206, 2001 May.
As with many complex genetic diseases, genome scans for prostate cancer have given conflicting results, often failing to provide replication of previous findings. One factor contributing to the lack of consistency across studies is locus heterogeneit... Back to top
Article 16 of 50
Scatter factor-hepatocyte growth factor elevation in the serum of patients with prostate cancer. - Journal of Urology. 165(4):1325-8, 2001 Apr.
PURPOSE: Scatter factor (SF), also known as hepatocyte growth factor (HGF), has been shown to induce proliferation, scattering and invasiveness in human prostate cancer cell lines. In this study we determined the serum level of SF-HGF in me... Back to top
Article 17 of 50
Efficacy of first-generation Cavermap to verify location and function of cavernous nerves during radical prostatectomy: a multi-institutional evaluation by experienced surgeons. - Urology. 57(3):491-4, 2001 Mar.
OBJECTIVES: To evaluate, using five experienced surgeons, the efficacy of the first-generation Cavermap Surgical Aid to identify the cavernous nerves intraoperatively and to predict the recovery of sexual function. This study was not design... Back to top
Article 18 of 50
Autosomal dominant inheritance of prostate cancer: a confirmatory study. - Urology. 57(1):97-101, 2001 Jan.
OBJECTIVES: To confirm, in a study of a large, independent cohort of families with prostate cancer, the findings of three segregation analyses that have suggested the existence of an inherited form of prostate cancer with an autosomal domin... Back to top
Article 19 of 50
Impaired prostate tumorigenesis in Egr1-deficient mice. - Nature Medicine. 7(1):101-7, 2001 Jan.
The transcription factor early growth response protein 1 (EGR1) is overexpressed in a majority of human prostate cancers and is implicated in the regulation of several genes important for prostate tumor progression. Here we have assessed the effect o... Back to top
Article 20 of 50
Prostate cancer aggressiveness locus on chromosome 7q32-q33 identified by linkage and allelic imbalance studies. - Neoplasia. 4(5):424-431, 2002 Sep-Oct.
The biologic aggressiveness of prostate tumors is an important indicator of prognosis. Chromosome 7q32-q33 was recently reported to show linkage to more aggressive prostate cancer, based on Gleason score, in a large sibling pair study. We report conf... Back to top
Article 21 of 50
Screening for prostate cancer in high risk populations. - Journal of Urology. 168(5):1980-3; discussion 1983-4, 2002 Nov.
PURPOSE: Black men and men with a family history of prostate cancer are at higher risk for this disease and may have an earlier age of onset. Consequently, screening at a younger age has been recommended for high risk men, however, there ar... Back to top
Article 22 of 50
Prostate-specific antigen cutoff of 2.6 ng/mL for prostate cancer screening is associated with favorable pathologic tumor features. - Urology. 60(3):469-73; discussion 473-4, 2002 Sep.
OBJECTIVES: To evaluate the pathologic characteristics of clinical Stage T1c (nonpalpable, prostate-specific antigen [PSA]-detected) prostate cancers detected in the 2.6 to 4.0-ng/mL PSA range and compare them with Stage T1c cancers concurr... Back to top
Article 23 of 50
Robustness of free prostate specific antigen measurements to reduce unnecessary biopsies in the 2.6 to 4.0 ng./ml. range. - Journal of Urology. 168(3):922-5, 2002 Sep.
PURPOSE: Prostate specific antigen (PSA) cutoffs lower than 4.0 ng./ml. are being evaluated more frequently but lower PSA cutoffs increase the number of prostatic biopsies. PSA exists in several forms free and complexed to proteins. Percent... Back to top
Article 24 of 50
Association studies of serum prostate-specific antigen levels and the genetic polymorphisms at the androgen receptor and prostate-specific antigen genes. - Cancer Epidemiology, Biomarkers & Prevention. 11(7):664-9, 2002 Jul.
Testing for serum prostate-specific antigen (PSA) levels has been widely used to screen for prostate cancer. However, PSA testing has low specificity and sensitivity because PSA is not prostate cancer-specific. PSA is encoded by the APS gene, and the... Back to top
Article 25 of 50
Serial biopsy results in prostate cancer screening study. - Journal of Urology. 167(6):2435-9, 2002 Jun.
PURPOSE: We evaluated prostate biopsy results in men with elevated prostate specific antigen (PSA) levels and/or suspicious digital rectal examination whose initial biopsies did not reveal cancer. MATERIALS AND METHODS: A t... Back to top
Article 26 of 50
Strategies combining total and percent free prostate specific antigen for detecting prostate cancer: a prospective evaluation. - Journal of Urology. 167(6):2427-34, 2002 Jun.
PURPOSE: Determining total prostate specific antigen (PSA) in plasma can often identify men who are subsequently diagnosed with prostate cancer. However, excess false-positives create large financial and psychological burdens in prostate ca... Back to top
Article 27 of 50
Patient preferences for outcomes associated with surgical management of prostate cancer. - Journal of Urology. 167(5):2117-22, 2002 May.
PURPOSE: We used utility assessment to evaluate patient preferences for current urinary and sexual function after radical prostatectomy. MATERIALS AND METHODS: We measured preferences in 209 community volunteers enrolled in... Back to top
Article 28 of 50
Identification of a gene frequently mutated in prostate tumors. - Medical Oncology. 18(3):179-87, 2001.
Although prostate cancer is the second leading cause of cancer death for men in the United States, the genetics of tumor development are poorly understood. Several expressed sequence tagged genes (ESTs) that are expressed predominantly in the prostat... Back to top
Article 29 of 50
Expression Profiling Reveals Hepsin Overexpression in Prostate Cancer¹ - Cancer Research, August 2001
Abstract Prostate cancer is the most commonly diagnosed noncutaneous cancer in men. Despite this fact, many of the genetic changes that coincide with prostate cancer progression remain enigmatic. We have addressed this problem by characterizing th... journal/cancerresearch_article312.htm Back to top
Article 30 of 50
'Extreme' prostate biopsies: Too many or not enough? - Urology Times 29, 2001
Leading urologic researchers, including several speakers at the AUA annual meeting, have issued a needle-sharp advisory to urologists who perform prostate biopsies: more samples are warranted, and they need to be taken in a single setting. You could ... journal/UrologyTimes_article316.htm Back to top
Article 31 of 50
Genetics of Prostate Cancer - AUA News 6, 2001
There are substantial differences in the prevalence of prostate cancer (CaP) among populations. However, men whose father or brother have CaP, those with multiple relatives with CaP, and those whose brother had early age-of-onset disease have a highe... journal/AUANews_article315.htm Back to top
Article 32 of 50
Polymorphisms in the Prostate Cancer Susceptibility Gene HPC2/ELA C2 in Multiplex Families and Healthy Controls¹ - Cancer Research 61: 4982-4984, 2001
Abstract Two polymorphisms in the newly cloned prostate cancer susceptibility gene, HPC2/ELAC2, are suspected to be associated with an increased risk of developing the disease. These missense variants result in a serine (S) to leucine (L) substitu... journal/CancerResearch_article313.htm Back to top
Article 33 of 50
Model-Free Linkage Analysis with Covariates Confirms Linkage of Prostate Cancer to Chromosomes 1 and 4 - Amer J Hum Genet 68: 1197-1206, 2001
As with many complex genetic diseases, genome scans for prostate cancer have given conflicting results, often failing to provide replication of previous findings. One factor contributing to the lack of consistency across studies is locus heterogeneit... journal/AmericanJournal_article311.htm Back to top
Article 34 of 50
Scatter Factor-Hepatocyte Growth Factor Elevation In The Serum Of Patients With Prostate Cancer - J Urol 165: 1325-1328, 2001
ABSTRACT Purpose: Scatter factor (SF), also known as hepatocyte growth factor {HGF), has been shown to induce proliferation, scattering and invasiveness in human prostate cancer cell lines. In this study we determined the serum level of SF-HGF in ... journal/journalurology_article310.htm Back to top
Article 35 of 50
Autosomal Dominant Inheritance Of Prostate Cancer: A Confirmatory Study. - Urol 57: 97-101, 2001
ABSTRACT Objectives. To confirm, in a study of a large, independent cohort of families with prostate cancer, the findings of three segregation analyses that have suggested the existence of an inherited form of prostate cancer with an autosomal dom... journal/Urology_article308.htm Back to top
Article 36 of 50
Efficacy Of First-Generation Cavermap To Verify Location And Function Of Cavernous Nerves During Radical Prostatectomy: A Multi-Institutional Evaluation By Experienced Surgeons - Urol 57: 491-494, 2001
ABSTRACT Objectives. To evaluate, using five experienced surgeons, the efficacy of the first-generation Cavermap Surgical Aid to identify the cavernous nerves intraoperatively and to predict the recovery of sexual function. This study was not desi... journal/Urology_article309.htm Back to top
Article 37 of 50
Impaired prostate tumorigenesis in Egr1-deficient mice - Nature Medicine 7:101-107, 2001
The transcription factor, early growth response protein 1 (EGR1), is overexpressed in a majority of human prostate cancers and is implicated in the regulation of several genes important for prostate tumor progression. Here we have assessed the effect... journal/naturemedicine_article307.htm Back to top
Article 38 of 50
Visual Estimate of the Percentage of Carcinoma Is an Independent Predictor of Prostate Carcinoma Recurrence after Radical Prostatectomy - Cancer 2000; 89;1308-14
BACKGROUND. The importance of tumor size measurements as predictors of disease recurrence after radical prostatectomy in patients with prostate carcinoma remains somewhat controversial, and many pathologists do not report these measurements routinely... journal/cancer_article304.htm Back to top
Article 39 of 50
Radical prostatectomy for localized prostate cancer provides durable cancer control with excellent quality of life. - THE JOURNAL OF UROLOGY 2000;163:1802-1807
Purpose: To cure localized prostate cancer, the entire prostate must be eliminated, which is what all forms of treatment must achieve. Although there is no better way to cure localized disease than total surgical removal, the challenge is w... Back to top
Article 40 of 50
Prostate cancer detection at low prostate specific antigen. - THE JOURNAL OF UROLOGY 2000;163:806-812
Purpose: At low prostate specific antigen (PSA) the indication for prostate biopsy is usually an abnormal digital rectal examination. We evaluate the diagnostic value of PSA, digital rectal examination, transrectal ultrasonography and tumor... Back to top
Article 41 of 50
Comparison of percent free PSA, PSA density, and age-specific PSA cutoffs for prostate cancer detection and staging. - Urology 2000 Aug 1;56(2):255-60
Objectives. Various methods have been proposed to increase the specificity of prostate-specific antigen (PSA), including age-specific PSA reference ranges, PSA density (PSAD), and percent free PSA (%fPSA). In this multicenter study, w... Back to top
Article 42 of 50
Identification and fine mapping of a region showing a high frequency of allelic imbalance on chromosome 16q23.2 that corresponds to a prostate cancer susceptibility locus. - Cancer Research 2000 Aug 1;56(2):255-60
Linkage to a prostate cancer susceptibility locus was recently reported on chromosome 16q23. We now report a region exhibiting a high frequency of allelic imbalance (AI) corresponding to this locus in tumors from 51 men diagnosed with prostate cancer... Back to top
Article 43 of 50
Genomewide scan for prostate cancer-aggressiveness loci. - Am J Hum Genet 2000 Jul;67(1):92-9
The aggressiveness of prostate cancer (PCa) varies widely: some tumors progress to invasive, potentially life-threatening disease, whereas others stay latent for the remainder of an individual's lifetime. The mechanisms resulting in this varia... Back to top
Article 44 of 50
Lowering PSA cutoffs to enhance detection of curable prostate cancer - Urology 55(6):791-795, 2000 Jun
The widespread use of serum prostate-specific antigen (PSA) testing for early prostate cancer detection has increased the proportion of early-stage cancers detected and is at least partially responsible for the recent decrease in prostate cancer mort... /journal/Urology_article295.htm Back to top
Article 45 of 50
Tissue factor expression and angiogenesis in human prostate carcinoma. - Hum Pathol 2000 Apr;31(4):443-7
In tumors, the switch to the angiogenic phenotype is thought to be controlled by a balance of positive and negative angiogenic factors. Tissue factor (TF) produced by tumor cells has been implicated in the regulation of this "angiogenic switch... Back to top
Article 46 of 50
Quality-of-life outcomes for men with prostate carcinoma detected by screening. - Cancer 2000 Mar 15;88(6):1454-63
BACKGROUND: There is limited information on outcomes of prostate carcinoma treatments given to screened patient populations for whom cancer is usually detected at an earlier stage. METHODS: The authors conducted a cross... Back to top
Article 47 of 50
A genome screen of multiplex sibships with prostate cancer. - Am J Hum Genet 2000 Mar;66(3):933-44
Analysis of a genome screen of 504 brothers with prostate cancer (CaP) who were from 230 multiplex sibships identified five regions with nominally positive linkage signals, on chromosomes 2q, 12p, 15q, 16p, and 16q. The strongest signal in the... Back to top
Article 48 of 50
Primary treatment choices for men with clinically localized prostate carcinoma detected by screening. - Cancer 2000 Mar 1;88(5):1122-30
BACKGROUND: Increasingly, prostate carcinoma is diagnosed through screening. However, little is known regarding factors that influence a patient's decision concerning the treatment choices presented to him. METHODS: Subjects were prosta... Back to top
Article 49 of 50
Percentage of free PSA in black versus white men for detection and staging of prostate cancer: a prospective multicenter clinical trial. - Urology 2000 Mar;55(3):372-6
OBJECTIVES: In predominately white populations, measurement of the percentage of free prostate-specific antigen (%fPSA) has been shown to enhance the specificity of total PSA testing for prostate cancer while maintaining high sensitivit... Back to top
Article 50 of 50
Pain and morbidity of transrectal ultrasound guided prostate biopsy: a prospective randomized trial of 6 versus 12 cores. - J Urol 2000 Jan;163(1):168-71
PURPOSE: An increasing number of studies suggest that 6-sector transrectal ultrasound guided biopsy of the prostate provides insufficient material to detect all clinically important prostate cancers and more cores may improve detection ... Back to top
Additional Journal Articles